Sai Parenterals Ltd

Sai Parenterals Ltd

Sai Parenterals Ltd, an integrated CDMO and branded generics enterprise, has announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its OTC Medicines Supply Agreement with one of Australia's leading pharmacy chains. The renewal carries an expanded product portfolio, a long agreement tenure, and a higher agreement value, and is projected at AUD 30 million over a three-year term.

Sai Parenterals Ltd

Sai Parenterals Ltd's subsidiary Noumed Pharmaceuticals has renewed a long-term OTC medicines supply agreement with a leading Australian pharmacy chain, with a 3-year term and a projected value of AUD 30 million (approximately Rs. 204 crores).

Sai Parenterals Ltd

Sai Parenterals Ltd has announced an analyst/institutional investor meeting on August 31, 2026, to be held in Mumbai. The meeting will be in person and hosted by Strategic Growth Advisors Pvt. Ltd. No unpublished price-sensitive information will be shared.

Sai Parenterals Ltd

Sai Parenterals Ltd has published a notice of its 25th Annual General Meeting (AGM) for the financial year 2025-26, to be held on September 10, 2026, through video conferencing.

Sai Parenterals Ltd

Sai Parenterals Ltd announced submission of newspaper publication in PAS-1 for change and variation in the objects of utilization of IPO proceeds.

Sai Parenterals Ltd

Sai Parenterals Ltd has announced the book closure and cut-off date for its 25th Annual General Meeting, scheduled to be held on September 10, 2026, through video conference. The register of members and share transfer books will be closed from September 4 to 10, 2026.

Sai Parenterals Ltd

Sai Parenterals Ltd submitted its 25th Annual Report for FY 2025-26 under Regulation 34 of SEBI (LODR) Regulations, 2015. The report is dispatched to shareholders on 19th August, 2026, and the Annual General Meeting is scheduled for 10th September, 2026.

Sai Parenterals Ltd

Sai Parenterals Ltd has announced the notice of its 25th Annual General Meeting for the financial year 2025-26, scheduled to be held on September 10, 2026, through video conference.

Sai Parenterals Ltd

Sai Parenterals Ltd has announced its Q1 FY 2027 earnings, with consolidated revenue of Rs. 182 crores, gross profit of Rs. 76 crores, EBITDA of Rs. 27 crores, and profit after tax of Rs. 8 crores. The company has also announced a proposed variation in the objects of the IPO issue, redeploying Rs. 101.85 crores towards majority stakes in two operating pharmaceutical assets.

Sai Parenterals Ltd

Sai Parenterals Ltd has made the audio recording of its Q1 2026 earnings call available on its website.

Sai Parenterals Ltd

Sai Parenterals Ltd has disclosed its investor presentation for Q1 FY 2027, highlighting its global IP-led pharmaceutical platform, integrated CDMO and branded generics enterprise, and long-term contracted international revenue. The company has a strong R&D-driven CDMO engine, with a 7.5-year exclusive OTC supply agreement in Australia and a 4-year exclusive anti-tuberculosis contract in the Philippines.

Sai Parenterals Ltd

Sai Parenterals Limited has announced its un-audited Financial Results for the quarter ended 30th June 2026, with total revenue of Rs. 182.4 crore, gross profit of Rs. 76.2 crore, EBITDA of Rs. 27.3 crore, and PAT of Rs. 7.9 crore.

Sai Parenterals Ltd

Sai Parenterals Ltd has submitted a statement on deviation or variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed that there are no deviations or variations in the utilization of the proceeds of the Initial Public Offer (IPO) during the quarter ended June 30, 2026.

Sai Parenterals Ltd

Sai Parenterals Ltd announced changes in management, including the re-appointment of Mr. Anil Kumar Karusala as Director and Managing Director, and the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer. The company also announced the acquisition of a greenfield injectables manufacturing plant and an existing R&D facility, and the ratification of its employee stock option plan.

Sai Parenterals Ltd

Sai Parenterals Ltd announced unaudited financial results for the quarter ended 30.06.2026, along with various board decisions and related party transactions. The company reported a change in the utilization of IPO proceeds, acquisition of a greenfield injectables manufacturing plant, and incorporation of a new step-down subsidiary in the US. The board also re-appointed directors, ratified the ESOP scheme, and approved related party transactions.

Sai Parenterals Ltd

Sai Parenterals Ltd held a board meeting on August 11, 2026, and approved several items, including un-audited financial results for the quarter ended June 30, 2026, and the re-appointment of directors. The company also announced the acquisition of a greenfield injectables manufacturing plant and the acquisition of an existing R&D facility. Additionally, the company ratified the Sai Parenterals Limited Employee Stock Option Plan, 2025, and the extension of benefits to subsidiary companies.

Sai Parenterals Ltd

Sai Parenterals Ltd has scheduled a Q1 FY 2026-27 earnings conference call for 12th August 2026 to discuss its operational and financial performance for the quarter ended 30th June 2026.

Sai Parenterals Ltd

Sai Parenterals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 11/08/2026 to consider un-audited financial results for the quarter ended June 30, 2026.